389 related articles for article (PubMed ID: 21721074)
1. Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations.
Magnusson T; Haase R; Schleef M; Wagner E; Ogris M
J Gene Med; 2011 Jul; 13(7-8):382-91. PubMed ID: 21721074
[TBL] [Abstract][Full Text] [Related]
2. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter.
Yew NS; Przybylska M; Ziegler RJ; Liu D; Cheng SH
Mol Ther; 2001 Jul; 4(1):75-82. PubMed ID: 11472109
[TBL] [Abstract][Full Text] [Related]
3. Sustained liver-specific transgene expression from the albumin promoter in mice following hydrodynamic plasmid DNA delivery.
Wooddell CI; Reppen T; Wolff JA; Herweijer H
J Gene Med; 2008 May; 10(5):551-63. PubMed ID: 18330848
[TBL] [Abstract][Full Text] [Related]
4. Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter.
Gill DR; Smyth SE; Goddard CA; Pringle IA; Higgins CF; Colledge WH; Hyde SC
Gene Ther; 2001 Oct; 8(20):1539-46. PubMed ID: 11704814
[TBL] [Abstract][Full Text] [Related]
5. Activator protein 1-mediated transcriptional regulation strategy sustains long-term expression of a xenogeneic gene product in vivo: an implication for gene therapy targeting congenital protein deficiencies.
Sasaki S; Smith JM; Takase K; Okuda K; Ishii N; Takeshita F
Int J Mol Med; 2006 Aug; 18(2):289-97. PubMed ID: 16820937
[TBL] [Abstract][Full Text] [Related]
6. CpG-free plasmid expression cassettes for cystic fibrosis gene therapy.
Pringle IA; Hyde SC; Connolly MM; Lawton AE; Xu B; Nunez-Alonso G; Davies LA; Sumner-Jones SG; Gill DR
Biomaterials; 2012 Oct; 33(28):6833-42. PubMed ID: 22727465
[TBL] [Abstract][Full Text] [Related]
7. CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression.
Liu BH; Wang X; Ma YX; Wang S
Gene Ther; 2004 Jan; 11(1):52-60. PubMed ID: 14681697
[TBL] [Abstract][Full Text] [Related]
8. Transgene loss and changes in the promoter methylation status as determinants for expression duration in nonviral gene transfer for factor IX.
Schüttrumpf J; Milanov P; Abriss D; Roth S; Tonn T; Seifried E
Hum Gene Ther; 2011 Jan; 22(1):101-6. PubMed ID: 20677911
[TBL] [Abstract][Full Text] [Related]
9. Time course of gene expression after plasmid DNA gene transfer to the liver.
Herweijer H; Zhang G; Subbotin VM; Budker V; Williams P; Wolff JA
J Gene Med; 2001; 3(3):280-91. PubMed ID: 11437333
[TBL] [Abstract][Full Text] [Related]
10. Low generation PAMAM dendrimer and CpG free plasmids allow targeted and extended transgene expression in tumors after systemic delivery.
Navarro G; Maiwald G; Haase R; Rogach AL; Wagner E; de Ilarduya CT; Ogris M
J Control Release; 2010 Aug; 146(1):99-105. PubMed ID: 20438778
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte-specific gene expression from integrated lentiviral vectors.
Nash KL; Jamil B; Maguire AJ; Alexander GJ; Lever AM
J Gene Med; 2004 Sep; 6(9):974-83. PubMed ID: 15352070
[TBL] [Abstract][Full Text] [Related]
12. Muscle creatine kinase/SV40 hybrid promoter for muscle-targeted long-term transgene expression.
Takeshita F; Takase K; Tozuka M; Saha S; Okuda K; Ishii N; Sasaki S
Int J Mol Med; 2007 Feb; 19(2):309-15. PubMed ID: 17203206
[TBL] [Abstract][Full Text] [Related]
13. Optimization of plasmid vectors for high-level expression in lung epithelial cells.
Yew NS; Wysokenski DM; Wang KX; Ziegler RJ; Marshall J; McNeilly D; Cherry M; Osburn W; Cheng SH
Hum Gene Ther; 1997 Mar; 8(5):575-84. PubMed ID: 9095409
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Tet-on system to avoid transgene down-regulation in ex vivo gene transfer to the CNS.
Johansen J; Rosenblad C; Andsberg K; Møller A; Lundberg C; Björlund A; Johansen TE
Gene Ther; 2002 Oct; 9(19):1291-301. PubMed ID: 12224012
[TBL] [Abstract][Full Text] [Related]
15. Sustained expression after nonviral ocular gene transfer using mammalian promoters.
Kachi S; Esumi N; Zack DJ; Campochiaro PA
Gene Ther; 2006 May; 13(9):798-804. PubMed ID: 16467860
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer.
Guo ZS; Wang LH; Eisensmith RC; Woo SL
Gene Ther; 1996 Sep; 3(9):802-10. PubMed ID: 8875229
[TBL] [Abstract][Full Text] [Related]
17. Lentiviral vectors for enhanced gene expression in human hematopoietic cells.
Ramezani A; Hawley TS; Hawley RG
Mol Ther; 2000 Nov; 2(5):458-69. PubMed ID: 11082319
[TBL] [Abstract][Full Text] [Related]
18. Improved neuronal transgene expression from an AAV-2 vector with a hybrid CMV enhancer/PDGF-beta promoter.
Wang CY; Guo HY; Lim TM; Ng YK; Neo HP; Hwang PY; Yee WC; Wang S
J Gene Med; 2005 Jul; 7(7):945-55. PubMed ID: 15756650
[TBL] [Abstract][Full Text] [Related]
19. Hydrodynamic plasmid DNA gene therapy model in liver transplantation.
Tsoulfas G; Takahashi Y; Liu D; Yagnik G; Wu T; Murase N; Geller DA
J Surg Res; 2006 Oct; 135(2):242-9. PubMed ID: 16926028
[TBL] [Abstract][Full Text] [Related]
20. Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression.
Mitsui M; Nishikawa M; Zang L; Ando M; Hattori K; Takahashi Y; Watanabe Y; Takakura Y
J Gene Med; 2009 May; 11(5):435-43. PubMed ID: 19291673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
